Brookline Capital Management Predicts XFOR FY2024 Earnings

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) – Investment analysts at Brookline Capital Management dropped their FY2024 earnings per share estimates for shares of X4 Pharmaceuticals in a report issued on Monday, January 6th. Brookline Capital Management analyst L. Cann now forecasts that the company will post earnings per share of ($0.67) for the year, down from their previous estimate of ($0.62). The consensus estimate for X4 Pharmaceuticals’ current full-year earnings is ($0.50) per share. Brookline Capital Management also issued estimates for X4 Pharmaceuticals’ Q4 2024 earnings at ($0.16) EPS, FY2025 earnings at ($0.78) EPS, FY2026 earnings at ($0.27) EPS and FY2027 earnings at $0.42 EPS.

Several other research firms have also issued reports on XFOR. Stifel Nicolaus cut their target price on X4 Pharmaceuticals from $5.00 to $4.00 and set a “buy” rating on the stock in a research note on Thursday, November 14th. HC Wainwright cut their price objective on shares of X4 Pharmaceuticals from $5.00 to $1.50 and set a “buy” rating on the stock in a research report on Thursday, November 14th.

X4 Pharmaceuticals Trading Down 10.4 %

XFOR opened at $0.57 on Thursday. The company has a current ratio of 4.89, a quick ratio of 4.80 and a debt-to-equity ratio of 1.26. The firm has a market cap of $97.23 million, a price-to-earnings ratio of -6.33 and a beta of 0.14. X4 Pharmaceuticals has a 12 month low of $0.26 and a 12 month high of $1.60. The stock has a fifty day moving average price of $0.55 and a 200-day moving average price of $0.62.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp grew its position in X4 Pharmaceuticals by 39.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 469,372 shares of the company’s stock worth $272,000 after purchasing an additional 133,398 shares during the last quarter. Rhumbline Advisers lifted its stake in shares of X4 Pharmaceuticals by 14.6% during the second quarter. Rhumbline Advisers now owns 187,246 shares of the company’s stock worth $109,000 after buying an additional 23,831 shares during the period. XTX Topco Ltd purchased a new stake in shares of X4 Pharmaceuticals during the second quarter valued at $65,000. Ensign Peak Advisors Inc increased its position in shares of X4 Pharmaceuticals by 4.6% in the 2nd quarter. Ensign Peak Advisors Inc now owns 2,546,458 shares of the company’s stock valued at $1,477,000 after acquiring an additional 111,032 shares during the period. Finally, K2 Principal Fund L.P. acquired a new position in shares of X4 Pharmaceuticals in the 2nd quarter valued at $284,000. 72.03% of the stock is currently owned by hedge funds and other institutional investors.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.